Precigen

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Palantir, Salesforce, Okta, Meta, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Intraday Update

Markets

Movers

Trading Ideas

BZAI

EVLV

GWRE

HIMX

LYTS

MVIS

OSIS

PGEN

Knight-Swift Transportation Posts Upbeat Earnings, Joins TAL Education, LSI Industries, GE Aerospace And Other Big Stocks Moving Higher On Thursday

FDA And CDC Involvement

Equities

Small Cap

Precigen Soars: Biologics License Application Submission For PRGN-2012 Targets First FDA-Approved Recurrent Respiratory Papillomatosis Treatment

Le 2 azioni finanziarie da scaricare ad agosto

Pre-Market Outlook

ARQT

SNOW

TITN

Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session

Precigen Inc

Pigeon Corp

Press Releases

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Earnings

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Precigen to Participate in the Stifel 2024 Healthcare Conference

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Offerings

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Abivax

AnaptysBio

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Immatics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Keros Therapeutics

Kura Oncology

LENZ Therapeutics

MeiraGTx Hldgs

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Opthea Limited - American Depositary Shares

Opthea

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

PureTech Health plc - American Depositary Shares

PureTech Health

Relay Therapeutics

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sage Therapeutics

Sana Biotechnology

Tyra Biosciences

Upstream Bio

Valneva

Verve Therapeutics

HC Wainwright & Co.

JMP Securities

Stifel

Comments

Precigen

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga